Focused on infectious disease therapies, this biotech firm reported a notable insider sale amid a year of strong share price ...

Biotech ETF BBC hits a 52-week high, likely fueled by strong clinical trial results and rising M&A activity, and renewed risk-on sentiment.

ASX biotech shares are trading at valuations that lag those of the US Nasdaq index. This discrepancy won't last, experts say.

Here’s a roundup of the most significant insider buying and selling activity disclosed on Tuesday for U.S. publicly traded companies. Top buys. Lipocine Inc. (NASDAQ:LPCN) saw D ...

This biotech innovator in antibody therapies for IBD reported a notable insider sale amid ongoing preclinical development ...

Ontario securities regulators are seeking millions of dollars in penalties against a London-area businessman for allegedly ...

That regulator is the U.S. Food and Drug Administration (FDA). In mid-March, it sent ImmunityBio a warning letter stating ...

Hørsholm, Denmark, 7 April 2026 - The Board of Directors of ExpreS2ion Biotech Holding AB (publ) ("ExpreS2ion" or the "Company") has today, on 7 April 2026, pursuant to the authorization granted by th ...

A York-based firm that makes treatments to reduce hunger and food cravings has reported a “strong period of growth and record start to 2026.” ...

I initiate coverage on Forte Biosciences stock at a 'Hold' rating due to both pipeline risk and upcoming clinical catalysts.

Adaptin Bio, Inc. (OTCQB: APTN), ('Adaptin” or the 'Company”), a biotechnology company developing precision cancer ...

Nigeria is losing an estimated $8–$9 billion annually to foreign shipping lines due to its absence in international maritime ...